Medical
-
According to Spyryx Biosciences, a Phase 1 study of its SPX-101, an inhaled SPLUNC1-derived peptide that the company is developing for the treatment of cystic fibrosis, showed that the drug was well tolerated, with no… Read more . . .
-
MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes… Read more . . .
-
Noveome Biotherapeutics has announced the publication of promising data from a preclinical study of its ST266 intranasal secretome showing anti-inflammatory activity and retinal ganglion cell (RGC) retention in the optic nerve in a mouse multiple… Read more . . .
-
Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year. Cipla Medpro CEO… Read more . . .
-
GlaxoSmithKline and Innoviva have announced the initiation of a Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol DPI compared to Relvar/Breo Ellipta for the treatment of asthma. GSK recently filed regulatory submissions for the FF/UMEC/VI DPI… Read more . . .
-
Aradigm Corporation has announced that top-line results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Pulmaquin inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (non-CF BE)… Read more . . .
-
Results from a study of Adherium’s Smartinhaler adherence monitoring system showing a 5-fold reduction in hospitalizations over a one-year period for children with poorly controlled asthma who used the device have been published online by… Read more . . .
-
Irish science center AMBER (Advanced Materials and BioEngineering Research), located at Trinity College Dublin, has announced that investigator Anne Marie Healy has received a €600,000 grant from the US National Institutes of Health (NIH) for… Read more . . .
-
Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome… Read more . . .
-
Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA